Aptahem AB (XSAT:APTA) Valuation Rank


XSAT:APTA Aptahem AB XSAT:APTA
30 GF Score
Price kr0.58
! 2 Warning Signs
View Full Analysis

What is Aptahem AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Aptahem AB Valuation Rank Related Terms

XSAT:APTA
30GF Score
Aptahem AB XSAT:APTA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aptahem AB Business Description

Address Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
30GF Score

Get the complete analysis for XSAT:APTA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.58
Price